Eckert & Ziegler Strahlen- und Medizintechnik AG
- WKN: 565970
- ISIN: DE0005659700
- Land: Deutschland
Nachricht vom 11.10.2021 | 12:20
Eckert & Ziegler Acquires 53,000 Square Feet Facility for Expansion of Contract Development and Manufacturing Services
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): Expansion
Berlin, 11 October 2021 - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) has received from the Berlin City Government a 66-year long-term lease for an industrial property with 53,000 square feet (5,000 square meters) of factory floor located at the north eastern city limit of Berlin. The group plans to use the facility for the expansion of its contract development and manufacturing services that it provides, among others, for a variety of cancer therapeutics and radio diagnostics. Up to 10 mm EUR will be invested during the next years into the renovation of the site, the set-up of new laboratories, production and clean rooms meeting Good Manufacturing Standards for the pharmaceutical industry, and the creation of high-tech workplaces. Due to its proximity to a thermal power station, the new site is expected to meet highest energy efficiencies.
"We are encouraged to see companies in our industry developing so many exciting new radiopharmaceuticals and are eager to provide a top-tier development and manufacturing service to support their efforts", explained Dr. Lutz Helmke, COO of Eckert & Ziegler's medical division. "We may also use the site later to produce proprietary drugs and diagnostics".
The acquisition and build-up of the new facility represent a cornerstone of Eckert & Ziegler's global capacity expansion program, which is scheduled to absorb up to 100 mm EUR until the end of the decade. It will also benefit Eckert & Ziegler sites in the United States and China. Production processes developed and validated in Berlin shall be duplicated there, so that customers in the pharmaceutical industries can receive the components for their radiopharmaceuticals in an identical, standardized manner.
About Eckert & Ziegler.
|Company:||Eckert & Ziegler Strahlen- und Medizintechnik AG|
|Phone:||+49 30 941084-138|
|Fax:||+49 30 941084-112|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1239745|
|End of News||DGAP News Service|
Eckert & Ziegler Partners with University Heal ...
Eckert & Ziegler Receives Approval for Gallium ...
Eckert & Ziegler Announces Clinical Trial Noti ...
Eckert & Ziegler: One-Off Effects and Robust O ...
Eckert & Ziegler Acquires Property for Radioph ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
01. Dezember 18:02 Bayer investiert in Nachhaltigkeit
01. Dezember 18:37 Shop Apotheke und Zur Rose? Beide haben noch Potenzial
01. Dezember 18:50 Bitcoin: Schlägt jetzt die Stunde der Bullen?
01. Dezember 19:00 Gold: Das klingt nicht gut
01. Dezember 19:48 Die OPEC tagt, TotalEnergies steigt
News im Fokus
Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025
01. Dezember 2021, 15:38
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
01. Dezember 2021